Company intelligence / Profile preview
ExoCoBio
Seoul, South Koreaexocobio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
ExoCoBio has developed both innovative therapeutic candidates and commercial cosmetic products based on proprietary stem cell-derived exosomes. The company operates the world’s first GMP-compliant facility dedicated to manufacturing these biologics. Clinical data specifics are not provided in the available sources, but the company claims global leadership in this field with active R&D and product launches.
- Therapeutic areas
- OtherDermatology
- Modalities
- exosome-based therapeutics and cosmeceuticals
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on ExoCoBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExoCoBio.